Abstracts tagged "osteoporosis"

Abstract Number: 304 • 2017 ACR/ARHP Annual Meeting
Usefulness of Consecutive Doppler Ultrasound Examinations for Detecting Deep Venous Thrombosis during the Perioperative Period in Patients with Osteoporotic Fractures of the Proximal Femur
Ken Nakaseko and Norihiro Mayumi, Department of Orthopaedic Surgery and Rheumatology, Kuwana City Medical Center, Kuwana Mie, Japan
Background/Purpose: Deep venous thrombosis (DVT) can lead to a venous thromboembolism and increase the risk of a pulmonary thromboembolism (PE). PE is one of the…
Abstract Number: 1229 • 2017 ACR/ARHP Annual Meeting
Factors Affecting FRAX Score Calculation & Treatment in Practice
Avneet Vig¹, Beverly Johnson², Tony Francis³ and Barbara Mendez-Agrusa⁴, ¹Montefiore Medical Center, Bronx, NY, ²Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, NY, ³Radiology, Albert Einstein College of Medicine, Bronx, NY, ⁴Medicine, Department of Rheumatology, Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Osteoporosis-related fractures causes increased disability and morbidity and mortality. The FRAX algorithm quantifies the 10 year probability of a hip or major osteoporotic fracture.…
Abstract Number: 2043 • 2017 ACR/ARHP Annual Meeting
Adherence to American College of Rheumatology Guidelines for Prevention of Glucocorticoid-Induced Osteoporosis in Patients with Polymyalgia Rheumatica
Brittany Frankel¹, Angela Christensen² and Monica Guma³, ¹Internal Medicine, University of California, San Diego, San Diego, CA, ²Rheumatology, University of California, San Diego, San Diego, CA, ³University of California, San Diego, San Diego, CA
Background/Purpose: American College of Rheumatology (ACR) 2010 guidelines recommend that any patient initiating glucocorticoid therapy with an anticipated duration of ≥3 months should receive a…
Abstract Number: 2379 • 2017 ACR/ARHP Annual Meeting
Effect of DKK-1 and Osteoprotegerin on Bone Mass in Tightly Controlled Rheumatoid Arthritis
Javier Narváez¹, Irene Martin-Esteve², Andrea Zacarias³, Pedro Alia⁴, Estibaliz Loza⁵, Loreto Carmona⁵, Joan Miquel Nolla² and Carmen Gomez Vaquero⁶, ¹Rheumatology Department, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain, ²Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ³Hospital Universitari de Bellvitge, Barcelona, Spain, ⁴Clinical Laboratory Service, Hospital Universitari de Bellvitge - IDIBELL, Barcelona, Spain, ⁵Instituto de Salud Musculoesquelética (InMusc), Madrid, Spain, ⁶Department of Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain
Background/Purpose: To analyze the association between osteoprotegerin (OPG) and Dickkopf-related protein 1 (DKK-1) and the annual percent change (Δ%) in bone mineral density (BMD) in patients…
Abstract Number: 361 • 2016 ACR/ARHP Annual Meeting
The Effect of Immunosuppressive and Antiresorptive Therapy on Bone Mineral Density in Lung Transplant Patients
Mireia Barceló-Bru¹, Sandra Farietta-Varela², Basilio Rodriguez-Díez¹, Mireia López-Corbeto², Ernesto Trallero-Araguás¹, Juan Jose De Agustin De Oro², Roxana Coras² and Agusti Sellas-Fernandez², ¹Rheumatology, Hospital Universitario Vall d´Hebron, Barcelona, Spain, ²Hospital Universitario Vall d´Hebron, Barcelona, Spain
Background/Purpose: Osteoporosis is a very frequent complication in recipients of a lung transplant . The factors that intervene can be previous to the transplant, such…
Abstract Number: 362 • 2016 ACR/ARHP Annual Meeting
Evaluation of Osteoporosis Risk Factors in Lung Transplant Patients
Sandra Farietta-Varela¹, Mireia Barceló-Bru², Basilio Rodriguez-Díez², Mireia López-Corbeto¹, Ernesto Trallero-Araguás², Juan Jose De Agustin De Oro¹, Roxana Coras¹ and Agusti Sellas-Fernandez¹, ¹Hospital Universitario Vall d´Hebron, Barcelona, Spain, ²Rheumatology, Hospital Universitario Vall d´Hebron, Barcelona, Spain
Background/Purpose: Patients with a terminal lung disease have a great number of risk factors for the development of osteoporosis. Although much has been learned about…
Abstract Number: 1025 • 2016 ACR/ARHP Annual Meeting
Assessment of the Effects of Switching Bisphosphonates to Denosumab or Daily Teriparatide in Patients with Rheumatoid Arthritis
Kosuke Ebina¹, Makoto Hirao², Jun Hashimoto³, Masao Yukioka⁴, Takaaki Noguchi⁵ and Hideki Yoshikawa⁶, ¹Orthopaedic Surgery, Osaka University Graduate School of Medicine, Osaka, Japan, ²Orthopaedic Surgery, Osaka University, Graduate School of Medicine, Suita, Japan, ³Dept of Rheumatology, Osaka-Minami Medical Center, Kawachinagano City, Japan, ⁴Orthopedic Surgery, Yukioka Hospital, Osaka, Japan, ⁵Orthopaedic Surgery, Osaka University, Graduate School of Medicine, Osaka, Japan, ⁶Department of Orthopedics, Osaka University Graduate School of Medicine, Suita Osaka, Japan
Background/Purpose: The efficacies of switching bisphosphonate (BP) to denosumab (DMAb), an anti-RANKL antibody which strongly inhibits bone resorption, or daily teriparatide (TPTD), a bone anabolic…
Abstract Number: 1026 • 2016 ACR/ARHP Annual Meeting
Morphea-like Skin Lesions Reported in the Phase 3 Long-Term Odanacatib Fracture Trial and Extension in Postmenopausal Women with Osteoporosis
Kenneth G. Saag¹, Tobie de Villiers², Peter Alexandersen³, Heidi Jacobe⁴, Carrie Kovarik⁵, Victoria P. Werth⁶, Albert Leung⁷, Avani Desai-Merchant⁸, Julie Mattaliano⁸ and Deborah Gurner⁸, ¹Department of Medicine, Division of Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, USA, Birmingham, AL, ²Mediclinic Panorama and Department of Obstetrics & Gynecology, University of Stellenbosch, Cape Town, South Africa, Cape Town, South Africa, ³Center for Clinical and Basic Research, Vejle, Denmark, Ballerup, Denmark, ⁴Department of Dermatology, University of Texas Southwestern Medical Center, Dallas, TX, ⁵Department of Dermatology, University of Pennsylvania, Philadelphia, PA, USA, Philadelphia, PA, ⁶Philadelphia VAMC, Philadelphia, PA, USA, Philadelphia, PA, ⁷Formerly Merck & Co., Inc., Kenilworth, NJ, USA, Kenilworth, NJ, ⁸Merck & Co., Inc., Kenilworth, NJ, USA, Kenilworth, NJ
Background/Purpose: LOFT was a double-blind, placebo-controlled trial. Women ≥65 years with total hip (TH) or femoral neck (FN) bone mineral density (BMD) T-score ≤-2.5, or…
Abstract Number: 1160 • 2016 ACR/ARHP Annual Meeting
Development of a Shared Decision Making Tool for Osteoporosis Treatment
Sonam Kiwalkar, Internal Medicine, Rochester General Hospital, Rochester, NY
Background/Purpose: In this era of modern medicine, health care providers and patients are partners in making decisions about treatment. It is imperative that evidence-based medicine…
Abstract Number: 1181 • 2016 ACR/ARHP Annual Meeting
Risk Factors for Incident Fractures in Patients with Systemic Lupus Erythematosus on Dialysis
Brian Le^1,2, Jennifer Waller³, Reshmitha Radhakrishnan⁴, Sun Jung Oh⁴, Monique Bethel^2,5, Christopher Rice⁴ and Laura Carbone^2,6, ¹Department of Internal Medicine, Augusta University, Augusta, GA, ²Specialty Care, Charlie Norwood VA Medical Center, Augusta, GA, ³Biostatistics, Augusta University, Augusta, GA, ⁴School of Medicine, Augusta University, Augusta, GA, ⁵1120 15th Street, BI 5070, Augusta University, Augusta, GA, ⁶Rheumatology, Augusta University, Augusta, GA
Background/Purpose: Osteoporosis and osteoporotic fractures are significant comorbidities in patients with systemic lupus erythematosus (SLE). Hip fractures are being increasingly recognized as a complication of…
Abstract Number: 1770 • 2016 ACR/ARHP Annual Meeting
The Impact of Comorbidities on Quality of Life in Systemic Lupus Erythematosus in the First 10 Years
Murray Urowitz¹, Dafna D Gladman², Nicole Anderson³, Jiandong Su⁴ and The Systemic Lupus International Collaborating Clinics (SLICC) Group , ¹Medicine, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ⁴Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada
The Impact of Comorbidities on Quality of Life in Systemic Lupus Erythematosus in the first 10 years Background/Purpose: The Medical Outcome Survey Short Form…
Abstract Number: 333 • 2016 ACR/ARHP Annual Meeting
An Assessment of Bone Health and Fracture Risk in a Bariatric Surgery Population at an Urban Medical Center
Sherilyn Diomampo¹, Leila Muhieddine², Ann Igoe³, Charles Thomas⁴ and Sobia Hassan¹, ¹Rheumatology, Case Western Reserve University, MetroHealth Medical Center, Cleveland, OH, ²Internal Medicine, Case Western Reserve University, MetroHealth Medical Center, Cleveland, OH, ³Medicine-Pediatrics, Case Western Reserve University, MetroHealth Medical Center, Cleveland, OH, ⁴Research, Case Western Reserve University, MetroHealth Medical Center, Cleveland, OH
Background/Purpose: Bariatric surgery is the most effective treatment for severe obesity.1,2 have been limited and conflicting reports as to the prevalence of osteoporosis and occurrence…
Abstract Number: 352 • 2015 ACR/ARHP Annual Meeting
Low Bone Density Is Associated with Atherosclerotic Disease in Patients with Psoriatic Arthritis
Eirik Ikdahl^1,2, Hege Kilander Høiberg³, Silvia Rollefstad², Andreas P Diamantopoulos^4,5, Grunde Wibetoe², Arthur Kavanaugh⁶, Inge C Olsen⁷, Tore K. Kvien⁷, Anne Grete Semb⁸ and Glenn Haugeberg⁹, ¹Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Preventive Cardio-Rheuma Clinic, Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Department of Rheumatology, Hospital of Southern Norway, Kristiansand, Norway, ⁴Rheumatology, Haugesund Hospital for Rheumatic Diseases, Haugesund, Norway, ⁵Rheumatology, Hospital of Southern Norway Trust, Kristiansand, Norway, ⁶University of California San Diego, La Jolla, CA, ⁷Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁸Diakonhjemmet Hospital, Oslo, Norway, ⁹Rheumatology, The Norwegian University of Science and Technology, Trondheim, Norway
Background/Purpose: There is an evidence vacuum concerning the mechanisms underlying the high atherosclerotic cardiovascular disease (ASCVD) burden in patients with psoriatic arthritis (PsA). In the…
Abstract Number: 367 • 2015 ACR/ARHP Annual Meeting
Prevention and Treatment of Bone Loss Following Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis
Xerxes Pundole¹, Maria A. Lopez-Olivo², Hira Cheema³, Gabriela Sanchez Petitto⁴, Maria E. Suarez-Almazor⁵ and Huifang Lu⁶, ¹General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, ²Department of General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, ³Texas Tech Odessa, Odessa, TX, ⁴The University of Texas, Health Science Center, Houston, TX, ⁵The Department of General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, ⁶General Internal Medicine, AT &EC, The University of Texas, MD Anderson Cancer Center, Houston, TX
Background/Purpose: The main goal of our study was to evaluate the efficacy and safety of bisphosphonates and/or general preventive strategies in the prevention and treatment…
Abstract Number: 380 • 2015 ACR/ARHP Annual Meeting
Osteoporosis Screening and Treatment of Rheumatoid Arthritis Patients at a Teaching Institution
Sheena Ogando¹, Calie Santana², Irene Blanco³ and Barbara Mendez¹, ¹Rheumatology, Montefiore Medical Center, Bronx, NY, ²Medicine, Montefiore Medical Center, Bronx, NY, ³Rheumatology, Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Glucocorticoids are effective at treating rheumatologic diseases but are known to increase fracture risk. In 2010, the ACR developed recommendations for the prevention…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].